Qiming Venture Partners Named One of ChinaVenture's 2025 Most LP-Focused VC Firms in China
The "ChinaVenture Ranking" is regarded as a bellwether for China's equity investment industry and serves as an important basis for capital commitments from many large institutional LPs.
Recently, ChinaVenture released its 2025 ChinaVenture Awards · Limited Partner Rankings. The "ChinaVenture Awards" are widely regarded as a bellwether for China's equity investment industry and serve as an important reference for major institutional LPs when making allocation decisions.
This year's selection includes awards such as ChinaVenture LP of the Year and Guide Fund of the Year. Qiming Venture Partners ranked in the Top 6 of the Most GP-Followed VC Firms in China.
Qiming Venture Partners
Ranked
Top 6 Most GP-Followed VC Firm in China
Selection Criteria
The 2025 ChinaVenture Most Industry-Followed Series rankings were determined through mutual voting between LPs and GPs, with additional consideration given to each firm's market influence and recognition by partners. The rankings reflect, to a meaningful degree, the industry standing and level of activity of LPs and GPs amid the evolving landscape of China's private equity market.
In the shifting tides of the venture capital market, every decision by a limited partner is a bet on the future. The 2025 ChinaVenture LP Rankings, through a rigorous lens, focus on active domestic LP groups in China, mapping out a vivid snapshot of the private equity investment ecosystem through multi-dimensional data analysis and in-depth research.
Source | ChinaVenture
Past Highlights
Qiming ESG | Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Relief Fund for Post-Disaster Reconstruction | Bilingual Qiming Perspectives | Duane Kuang, Qiming Venture Partners: Hong Kong Has Become a Critical International Financing Channel for Hard Tech Companies Qiming Honors | Qiming Venture Partners Wins Three Awards at China Venture Capital Research Institute's 2025 China Venture Capital Annual Golden Investment Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), GenScript ProBio (688520.SH), Hope Medicine, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, among others.